TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
GlaxoSmithKline AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
1,169,699
|
1,087,065
|
877,849 |
| Financial expenses |
3,993
|
1,588
|
401 |
| Earnings before taxes |
33,617
|
34,598
|
28,269 |
| EBITDA |
38,519
|
34,689
|
30,613 |
| Total assets |
451,313
|
348,057
|
334,704 |
| Current assets |
442,521
|
340,853
|
333,508 |
| Current liabilities |
355,653
|
252,904
|
244,649 |
| Equity capital |
95,450
|
94,946
|
87,278 |
| - share capital |
51,565
|
50,652
|
47,296 |
| Employees (average) |
71
|
76
|
70 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
21.1%
|
27.3%
|
26.1% |
| Turnover per employee |
16,475
|
14,303
|
12,541 |
| Profit as a percentage of turnover |
2.9%
|
3.2%
|
3.2% |
| Return on assets (ROA) |
8.3%
|
10.4%
|
8.6% |
| Current ratio |
124.4%
|
134.8%
|
136.3% |
| Return on equity (ROE) |
35.2%
|
36.4%
|
32.4% |
| Change turnover |
63,033
|
146,927
|
44,430 |
| Change turnover % |
6%
|
16%
|
5% |
| Chg. No. of employees |
-5
|
6
|
1 |
| Chg. No. of employees % |
-7%
|
9%
|
1% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.